藥物發現服務市場規模、佔有率和成長分析（按流程、類型、治療領域、藥物類型、技術、最終用戶和地區分類）－2026-2033年產業預測

全球藥物研發服務市場預計到 2024 年將達到 46.4 億美元，到 2025 年將達到 50.1 億美元，到 2033 年將達到 92.8 億美元，預測期（2026-2033 年）的複合年成長率為 8%。

全球藥物研發服務市場預計將迎來顯著成長，這主要得益於對創新治療方法的持續需求，以滿足包括神經退化性疾病、癌症、罕見遺傳疾病和心血管疾病在內的各種未被滿足的醫療需求。新疾病的出現進一步凸顯了對有效治療方法的迫切需求。然而，藥物研發的複雜性在於它需要毒理學、藥物化學和藥理學等領域專家的通力合作，因此，許多機構往往選擇將這些服務外包。這種策略使製藥公司和研究機構能夠在利用專業知識和基礎設施的同時，大幅節省成本並提高效率。舉措，研發投入的不斷增加，尤其是在罕見疾病和孤兒藥計畫方面的投入，也帶來了新的商機。然而，監管方面的挑戰和專業人才的短缺可能會構成潛在的障礙。

全球藥物研發服務市場促進因素

糖尿病、失智症和心血管疾病等慢性病的高發生率對死亡率產生了顯著影響，並佔全球死亡人數的很大比例。慢性病發病率的上升趨勢預計將推動全球藥物研發服務市場的成長。隨著對有效藥物的需求不斷成長，對創新藥物研發解決方案的需求也變得日益迫切。這反過來又為藥物研發公司提供了新的經濟機遇，使其能夠應對這些健康挑戰，從而推動研發進步，最終改善患者預後，並最終提升全球整體的健康福祉。

限制全球藥物研發服務市場的因素

監管機構在核准過程中優先考慮藥物的安全性和有效性，這對於確保市場上藥品的品質至關重要。然而，這些嚴格的要求顯著增加了藥物研發和最終產品的成本。在對價格敏感的新興經濟體中，這一因素尤其突出，不斷上漲的成本會阻礙新藥的可及性和應用。因此，遵守監管標準的財務負擔可能成為全球藥物研發服務市場的一大阻礙因素，限制了那些對藥品可負擔性要求極高的地區的製藥公司的發展機會。

全球藥物研發服務市場趨勢

全球藥物研發服務市場正呈現顯著上升趨勢，這主要得益於對新型治療方法日益成長的需求以及全球醫療保健產業的快速發展。慢性病盛行率的不斷攀升促使各國政府和製藥公司更加重視創新解決方案，從而加大了對臨床試驗的投資。隨著各機構尋求提升自身研發能力並簡化藥物開發流程，對開發有效新治療方法的日益重視也推動了對藥物研發服務的需求。因此，隨著相關人員不斷適應不斷變化的醫療保健格局和治療需求，預計該市場將迎來強勁成長。

目錄

介紹

• 調查目標
• 調查範圍
• 定義

調查方法

• 資訊收集
• 二手資料和一手資料方法
• 市場規模預測
• 市場假設與限制

執行摘要

• 全球市場展望
• 供需趨勢分析
• 細分市場機會分析

市場動態與展望

• 市場規模
• 市場動態
  • 促進因素和機遇
  • 限制與挑戰
• 波特分析

關鍵市場考察

• 關鍵成功因素
• 競爭程度
• 關鍵投資機會
• 市場生態系統
• 市場吸引力指數（2025）
• PESTEL 分析
• 總體經濟指標
• 價值鏈分析
• 定價分析
• 技術分析

全球藥物研發服務市場規模（按流程和複合年成長率分類）（2026-2033 年）

• 目標選擇
• 目標檢驗
• 命中先導化合物
• 候選物質檢驗
• 其他

全球藥物研發服務市場規模（按類型和複合年成長率分類）（2026-2033 年）

• 藥物化學
• 生物服務
• 藥物代謝
• 醫藥服務
• 藥物動力學

全球藥物研發服務市場規模（依治療領域分類）及複合年成長率（2026-2033 年）

• 腫瘤學
• 神經病學
• 循環系統疾病
• 呼吸系統疾病
• 糖尿病
• 其他

全球藥物研發服務市場規模（依藥物類型及複合年成長率分類）（2026-2033 年）

• 低分子化合物
• 生物製劑

全球藥物研發服務市場規模（依技術及複合年成長率分類）（2026-2033 年）

• 高通量篩檢
• 生物晶片
• 藥物基因學
• 奈米科技
• 光譜學

全球藥物研發服務市場規模（依最終用戶分類）及複合年成長率（2026-2033 年）

• 醫院和診所
• 製藥公司
• 生技公司
• 研究所

全球藥物研發服務市場規模及複合年成長率（2026-2033）

• 北美洲
  • 美國
  • 加拿大
• 歐洲
  • 德國
  • 西班牙
  • 法國
  • 英國
  • 義大利
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 印度
  • 日本
  • 韓國
  • 亞太其他地區
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地區
• 中東和非洲
  • 海灣合作理事會國家
  • 南非
  • 其他中東和非洲地區

競爭資訊

• 前五大公司對比
• 主要企業的市場定位（2025 年）
• 主要市場參與者所採取的策略
• 近期市場趨勢
• 公司市佔率分析（2025 年）
• 主要企業公司簡介
  • 公司詳情
  • 產品系列分析
  • 依業務板塊進行公司股票分析
  • 2023-2025年營收年比比較

主要企業簡介

• Charles River Laboratories（USA）
• WuXi AppTec（China）
• Thermo Fisher Scientific Inc.（USA）
• Evotec SE（Germany）
• Pharmaron（China）
• Labcorp（USA）
• Syngene International Limited（India）
• Eurofins Scientific（Luxembourg）
• Jubilant Biosys Limited（India）
• Curia Global, Inc.（USA）
• GenScript（USA）
• Frontage Holdings Corporation（USA）
• Piramal Enterprises Ltd.（India）
• Aragen Life Sciences Ltd.（India）
• Sygnature Discovery（UK）
• Selvita SA（Poland）
• Viva Biotech（China）
• TCG Lifesciences Pvt. Ltd.（India）
• Medicilon（China）
• Sai Life Sciences Limited（India）

結論與建議

Global Drug Discovery Services Market size was valued at USD 4.64 Billion in 2024 and is poised to grow from USD 5.01 Billion in 2025 to USD 9.28 Billion by 2033, growing at a CAGR of 8% during the forecast period (2026-2033).

The global drug discovery services market is poised for substantial growth driven by the persistent demand for innovative treatments addressing various unmet medical needs, including neurodegenerative, cancer, rare genetic, and cardiovascular diseases. The emergence of novel diseases further emphasizes the need for effective therapies. However, the intricate nature of drug discovery necessitates collaboration among experts in disciplines such as toxicology, medicinal chemistry, and pharmacology, often leading institutions to outsource these services. This strategy enables pharmaceutical companies and research organizations to leverage specialized expertise and infrastructure while achieving significant cost and time efficiencies. Moreover, increasing investments in R&D, particularly focused on rare diseases and orphan drug initiatives, highlight new revenue opportunities, even as regulatory challenges and a shortage of skilled professionals pose potential hurdles.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Drug Discovery Services market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Drug Discovery Services Market Segments Analysis

Global Drug Discovery Services Market is segmented by Process, Type, Therapeutic Area, Drug Type, Technology, End User and region. Based on Process, the market is segmented into Target Selection, Target Validation, Hit-To-Lead Identification, Candidate Validation and Others. Based on Type, the market is segmented into Medicinal Chemistry, Biology Services, Drug Metabolism, Pharmaceutical Services and Pharmacokinetics. Based on Therapeutic Area, the market is segmented into Oncology, Neurology, Cardiovascular Disease, Respiratory Disease, Diabetes and Others. Based on Drug Type, the market is segmented into Small Molecules and Biologics. Based on Technology, the market is segmented into High Throughput Screening, Biochips, Pharmacogenetics, Nanotechnology and Spectroscopy. Based on End User, the market is segmented into Hospital & Clinics, Pharmaceutical Companies, Biotechnology Companies and Research Institute. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Drug Discovery Services Market

The prevalence of chronic diseases such as diabetes, dementia, and cardiovascular conditions significantly impacts mortality rates, accounting for a substantial portion of global deaths. This rising incidence of chronic illnesses is anticipated to drive growth within the global drug discovery services market. As the demand for effective medications escalates, the need for innovative drug discovery solutions becomes increasingly vital. Consequently, companies specializing in drug discovery are presented with new economic opportunities to address these health challenges, fostering advancements in research and development aimed at improving patient outcomes and ultimately enhancing overall health and well-being worldwide.

Restraints in the Global Drug Discovery Services Market

Regulatory agencies prioritize safety and efficacy in drug approval processes, which are crucial for ensuring the quality of medicines in the market. However, these rigorous requirements substantially drive up the costs associated with drug development and the final product. This factor is particularly significant in price-sensitive emerging economies, where elevated costs can hinder the accessibility and adoption of new medications. As a result, the financial burden imposed by compliance with regulatory standards can pose a significant restraint on the Global Drug Discovery Services market, limiting opportunities for pharmaceutical companies in regions where affordability is critical.

Market Trends of the Global Drug Discovery Services Market

The Global Drug Discovery Services market is witnessing a significant upward trend driven by the increasing demand for novel therapies and the rapid advancement of the healthcare sector worldwide. The rising prevalence of chronic diseases has prompted a greater focus from governments and pharmaceutical companies on innovative solutions, leading to heightened investments in clinical trials. This growing emphasis on developing new and effective treatments is propelling the need for drug discovery services, as organizations seek to enhance their research capabilities and streamline the drug development process. Consequently, the market is poised for robust growth as stakeholders adapt to the evolving landscape of healthcare and therapeutic needs.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2025
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technology Analysis

Global Drug Discovery Services Market Size by Process & CAGR (2026-2033)

• Market Overview
• Target Selection
• Target Validation
• Hit-To-Lead Identification
• Candidate Validation
• Others

Global Drug Discovery Services Market Size by Type & CAGR (2026-2033)

• Market Overview
• Medicinal Chemistry
• Biology Services
• Drug Metabolism
• Pharmaceutical Services
• Pharmacokinetics

Global Drug Discovery Services Market Size by Therapeutic Area & CAGR (2026-2033)

• Market Overview
• Oncology
• Neurology
• Cardiovascular Disease
• Respiratory Disease
• Diabetes
• Others

Global Drug Discovery Services Market Size by Drug Type & CAGR (2026-2033)

• Market Overview
• Small Molecules
• Biologics

Global Drug Discovery Services Market Size by Technology & CAGR (2026-2033)

• Market Overview
• High Throughput Screening
• Biochips
• Pharmacogenetics
• Nanotechnology
• Spectroscopy

Global Drug Discovery Services Market Size by End User & CAGR (2026-2033)

• Market Overview
• Hospital & Clinics
• Pharmaceutical Companies
• Biotechnology Companies
• Research Institute

Global Drug Discovery Services Market Size & CAGR (2026-2033)

• North America (Process, Type, Therapeutic Area, Drug Type, Technology, End User)
  • US
  • Canada
• Europe (Process, Type, Therapeutic Area, Drug Type, Technology, End User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Process, Type, Therapeutic Area, Drug Type, Technology, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Process, Type, Therapeutic Area, Drug Type, Technology, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Process, Type, Therapeutic Area, Drug Type, Technology, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Charles River Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evotec SE (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmaron (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syngene International Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (Luxembourg)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Jubilant Biosys Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Curia Global, Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenScript (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Frontage Holdings Corporation (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Piramal Enterprises Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Aragen Life Sciences Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sygnature Discovery (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Selvita SA (Poland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viva Biotech (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• TCG Lifesciences Pvt. Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medicilon (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sai Life Sciences Limited (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations